Natco Pharma (NSE:NATCOPHARM) Piotroski F-Score: 4 (As of Jul. 04, 2026) — 33% Below Median


NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
89 GF Score
Price ₹931.40
GF Value ₹936.16
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma Piotroski F-Score?

Natco Pharma NSE:NATCOPHARM -0.33% 89 Piotroski F-Score is 4 as of Jul. 04, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 89/100 and a GF Value™ of ₹936.16 (Fairly Valued). The stock has 2 warning signs investors should review. Among 981 Drug Manufacturers companies, Natco Pharma ranks worse than 60.86% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Natco Pharma has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Natco Pharma's Piotroski F-Score or its related term are showing as below:

NSE:NATCOPHARM' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Natco Pharma was 8. The lowest was 4. And the median was 6.

Natco Pharma  (NSE:NATCOPHARM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Natco Pharma Piotroski F-Score Related Terms


Natco Pharma Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Natco Pharma's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma Piotroski F-Score Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 8.00 6.00 7.00 4.00

Natco Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 0.00 0.00 0.00 4.00

NSE:NATCOPHARM vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Piotroski F-Score falls into.


NSE:NATCOPHARM
89GF Score
Natco Pharma Ltd NSE:NATCOPHARM
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹14,185 Mil.
Cash Flow from Operations was ₹17,683 Mil.
Revenue was ₹40,783 Mil.
Gross Profit was ₹33,878 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (86308 + 110737) / 2 = ₹98522.5 Mil.
Total Assets at the begining of this year (Mar25) was ₹86,308 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,042 Mil.
Total Current Assets was ₹50,523 Mil.
Total Current Liabilities was ₹16,809 Mil.
Net Income was ₹18,854 Mil.

Revenue was ₹44,295 Mil.
Gross Profit was ₹37,397 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (69063 + 86308) / 2 = ₹77685.5 Mil.
Total Assets at the begining of last year (Mar24) was ₹69,063 Mil.
Long-Term Debt & Capital Lease Obligation was ₹46 Mil.
Total Current Assets was ₹52,700 Mil.
Total Current Liabilities was ₹9,435 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Natco Pharma's current Net Income (TTM) was 14,185. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Natco Pharma's current Cash Flow from Operations (TTM) was 17,683. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=14185/86308
=0.16435325

ROA (Last Year)=Net Income/Total Assets (Mar24)
=18854/69063
=0.27299712

Natco Pharma's return on assets of this year was 0.16435325. Natco Pharma's return on assets of last year was 0.27299712. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Natco Pharma's current Net Income (TTM) was 14,185. Natco Pharma's current Cash Flow from Operations (TTM) was 17,683. ==> 17,683 > 14,185 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1042/98522.5
=0.01057626

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=46/77685.5
=0.00059213

Natco Pharma's gearing of this year was 0.01057626. Natco Pharma's gearing of last year was 0.00059213. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=50523/16809
=3.00571123

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=52700/9435
=5.58558559

Natco Pharma's current ratio of this year was 3.00571123. Natco Pharma's current ratio of last year was 5.58558559. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Natco Pharma's number of shares in issue this year was 179.104. Natco Pharma's number of shares in issue last year was 179.118. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=33878/40783
=0.83068926

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=37397/44295
=0.84427136

Natco Pharma's gross margin of this year was 0.83068926. Natco Pharma's gross margin of last year was 0.84427136. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=40783/86308
=0.47252862

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=44295/69063
=0.64137092

Natco Pharma's asset turnover of this year was 0.47252862. Natco Pharma's asset turnover of last year was 0.64137092. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Natco Pharma has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Natco Pharma (NSE:NATCOPHARM) has a Piotroski F-Score of 4 as of Jul. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Natco Pharma and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Natco Pharma's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Natco Pharma ranks #597 out of 981 companies in the Drug Manufacturers industry, placing it in the top 60.9%.
Is Natco Pharma's Piotroski F-Score too high?
Natco Pharma's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Natco Pharma's value of 4 is 20% below this industry median. Based on the distribution chart, Natco Pharma ranks #597 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Natco Pharma ranks #597 out of 981 companies for Piotroski F-Score. This places Natco Pharma in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Natco Pharma's value of 4 is 20% below this benchmark. Historically, Natco Pharma's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Natco Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natco Pharma's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Natco Pharma and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natco Pharma's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.16, compared to a current price of ₹931.40 — trading 0.5% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Piotroski F-Score is 4 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued. The current stock price of ₹931.40 is trading 0.5% below its estimated GF Value™ of ₹936.16. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for NSE:NATCOPHARM:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: ₹936.16 vs. price of ₹931.40 (0.5% below fair value)
  • GF Score™: 89/100 with 2 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#597 of 981)

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score

Get the complete analysis for NSE:NATCOPHARM

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹931.40
Price
₹936.16
GF Value